Invuity, Inc. (IVTY) Receives Consensus Recommendation of “Buy” from Analysts

Invuity, Inc. (NASDAQ:IVTY) has earned a consensus recommendation of “Buy” from the seven research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $15.20.

A number of equities analysts have issued reports on the stock. Zacks Investment Research cut shares of Invuity from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Piper Jaffray Companies reissued a “buy” rating and set a $10.00 price target on shares of Invuity in a research report on Wednesday, July 26th. Northland Securities set a $13.00 price target on shares of Invuity and gave the stock a “buy” rating in a research report on Tuesday, June 13th. William Blair reissued a “buy” rating on shares of Invuity in a research report on Tuesday, May 23rd. Finally, Stifel Nicolaus reissued a “buy” rating and set a $10.00 price target (up from $9.00) on shares of Invuity in a research report on Thursday, April 27th.

COPYRIGHT VIOLATION WARNING: “Invuity, Inc. (IVTY) Receives Consensus Recommendation of “Buy” from Analysts” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.com-unik.info/2017/08/19/invuity-inc-ivty-receives-consensus-recommendation-of-buy-from-analysts-updated.html.

Shares of Invuity (NASDAQ:IVTY) traded down 0.41% during midday trading on Tuesday, hitting $6.10. The stock had a trading volume of 11,465 shares. The stock’s market cap is $104.01 million. The stock has a 50-day moving average of $7.37 and a 200 day moving average of $7.63. Invuity has a 52 week low of $4.50 and a 52 week high of $14.25.

Invuity (NASDAQ:IVTY) last announced its quarterly earnings data on Tuesday, July 25th. The medical instruments supplier reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by $0.07. Invuity had a negative net margin of 114.61% and a negative return on equity of 140.69%. The business had revenue of $9.77 million during the quarter, compared to the consensus estimate of $10.30 million. Analysts anticipate that Invuity will post ($2.38) EPS for the current fiscal year.

In other news, Director Eric W. Roberts purchased 5,000 shares of Invuity stock in a transaction dated Monday, May 15th. The shares were bought at an average cost of $7.88 per share, with a total value of $39,400.00. Following the completion of the transaction, the director now directly owns 101,529 shares in the company, valued at approximately $800,048.52. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Eric W. Roberts purchased 6,500 shares of Invuity stock in a transaction dated Thursday, May 18th. The shares were purchased at an average cost of $7.07 per share, for a total transaction of $45,955.00. Following the completion of the transaction, the director now owns 106,029 shares of the company’s stock, valued at $749,625.03. The disclosure for this purchase can be found here. Company insiders own 10.50% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Cowen Prime Services LLC boosted its stake in Invuity by 37.3% in the second quarter. Cowen Prime Services LLC now owns 470,050 shares of the medical instruments supplier’s stock valued at $3,408,000 after buying an additional 127,800 shares in the last quarter. Royce & Associates LP boosted its stake in Invuity by 141.9% in the second quarter. Royce & Associates LP now owns 98,939 shares of the medical instruments supplier’s stock valued at $717,000 after buying an additional 58,033 shares in the last quarter. Trexquant Investment LP boosted its stake in Invuity by 119.2% in the second quarter. Trexquant Investment LP now owns 34,580 shares of the medical instruments supplier’s stock valued at $251,000 after buying an additional 18,807 shares in the last quarter. CAPROCK Group Inc. bought a new stake in Invuity during the second quarter valued at approximately $254,000. Finally, Spark Investment Management LLC bought a new stake in Invuity during the second quarter valued at approximately $158,000. 69.58% of the stock is currently owned by institutional investors and hedge funds.

Invuity Company Profile

Analyst Recommendations for Invuity (NASDAQ:IVTY)

What are top analysts saying about Invuity Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Invuity Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit